Park member MicrosensDx has partnered with ProteoGenix to advance a new diagnostic test aimed at improving early detection of sepsis.
The collaboration will accelerate development of a novel biomarker-based ELISA test, designed to identify patients at risk of severe sepsis more quickly and accurately. With sepsis causing around 48,000 deaths annually in the UK, earlier diagnosis remains a critical unmet need.
MicrosensDx will draw on ProteoGenix’s antibody expertise as it moves the test towards clinical trials. Simon Walker, CEO of MicrosensDx, said: “We achieved promising results in detecting the oxidised biomarker during 2025, and this has given us the confidence to seek additional investment and begin scaling up in readiness for clinical trials.”